Zhe Fan

Zhe Fan

Auto-generated profile, based on publicly available information

Zhe Fan

Henan Institute of Advanced Technology, Zhengzhou University, Zhengzhou 450003, P.R. China; The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou 450052, P.R. China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2025 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
YZYingxin Zhang
Yingxin Zhang
ZFZhe Fan
Zhe Fan
JWJiankang Wang
Jiankang Wang
BGBing Guan
Bing Guan
FZFengyi Zhou
Fengyi Zhou
AHAimin Huang
Aimin Huang
Health inequalities intensified, burden shifting to low-resource regions despite preventive advancements. HPV and screening rates diverged by SDI, highlighting coverage gaps. Screening and vaccination inversely linked to disease burden, underscoring critical efficacy. Innovative modeling exposed disparities, advocating SDI-stratified interventions. This study analyzes global and regional cervical cancer trends (1990–2021) across different Socio-Demographic Index (SDI) levels, highlighting health inequalities, assessing the impact of HPV vaccination and screening, and modeling future trends. The findings aim to inform targeted prevention policies, reduce regional disparities, and promote global health equity. Data were sourced from the Global Burden of Disease study 2021(GBD 2021), OECD, and WHO. The focus was on incidence and disability-adjusted life years (DALYs) of cervical cancer. Time trends were analyzed by SDI regions, alongside health inequality assessments. Correlation analyses examined links between screening rates, HPV vaccination coverage, and disease burden. From 1990 to 2021, global age-standardized incidence rate and age-standardized DALYs rates declined significantly, with estimated annual percentage changes (EAPC) of -0.54% (95% CI: -0.63 to -0.44) and − 1.27% (95% CI: -1.36 to -1.18). However, significant differences exist in specific patterns of change across SDI regions: exhibited an upward incidence trajectory. From 1990 to 2021, the burden of cervical cancer disease shifted from developed to less developed regions. Correlation analysis showed negative associations between screening rates and DALYs (r = -0.56, p < 0.01) and between vaccination coverage and incidence (r = -0.35, p < 0.01). Although the global cervical cancer burden has decreased, significant regional disparities remain. Future policies should focus on tailored interventions, with low-resource regions strengthening healthcare infrastructure and implementing minimum effective preventive measures, while high-SDI regions shift to precision public health approaches. Policymakers must also incorporate culturally sensitive health education to address social barriers, challenge misconceptions, and empower communities, ultimately reducing preventable cervical cancer morbidity.

9 February 2026 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
ZFZhe Fan
Zhe Fan
MLMeng Li
Meng Li
KCKehan Cai
Kehan Cai
ZXZiying Xie
Ziying Xie
BLBotao Lu
Botao Lu
TCTao Chen
Tao Chen

26 March 2026 in RSC Advances
Verified
Journal Article
Open access
ZFZhe Fan
Zhe Fan
HZHuiying Zhang
Huiying Zhang
LWLulu Wang
Lulu Wang
JTJinxiang Tian
Jinxiang Tian
HJHuaiqing Jiang
Huaiqing Jiang
HYHaiyang Yu
Haiyang Yu
The repair of tumor-induced bone defects requires regenerative materials capable of functioning within the harsh conditions of cancer therapy.

1 October 2026 in Bioactive Materials
Verified
Journal Article
Open access
KCKehan Cai
Kehan Cai
ZFZhe Fan
Zhe Fan
JTJun Tan
Jun Tan
WCWei Cai
Wei Cai
MZMinghang Zhang
Minghang Zhang
TCTao Chen
Tao Chen
Cell membrane-camouflaged nanoparticles have emerged as powerful tools for targeted drug delivery; however, current strategies typically utilize membranes from static cell states, overlooking the dynamic functional evolution that occurs during lineage commitment. Here, we established a stepwise osteogenic differentiation model for BMSCs and isolated cell membranes from distinct stages of this process to construct a series of cell membrane–camouflaged mesoporous silica nanoparticles (CM-MSNs). Proteomic profiling revealed stage-dependent remodeling of membrane protein composition, with early osteogenic (EO) stage membranes uniquely enriched in phosphatases and cadherins. Functional evaluations showed stage-dependent activity among CM-MSNs, and EO membrane-camouflaged nanoparticles (EO-MSNs) exhibited the strongest capacity to promote calcium deposition and enhance BMSC osteogenesis in vitro via the Wnt/β-catenin signaling pathway. In a rat model of osteoporosis, EO-MSN exhibited prolonged circulation time, precise bone-specific accumulation, and potent anti-osteoporotic efficacy. Collectively, our findings suggest that utilizing stage-specific cell membranes offers a novel strategy to remodel the osteoporotic microenvironment by modulating the osteoblast-adipocyte equilibrium.

17 July 2026 in Cell Reports Medicine
Verified
Journal Article
Open access
ZFZhe Fan
Zhe Fan
PCPengfei Chen
Pengfei Chen
SZShuangmei Zuo
Shuangmei Zuo
KCKehan Cai
Kehan Cai
SLSitian Li
Sitian Li
Yazhou ChenYazhou Chen
Yazhou Chen
Current adoptive cell-based immunotherapies show limited efficacy against solid tumors, largely due to dynamic cellular phenotypic shifts and the immunosuppressive tumor microenvironment (TME). To address these challenges, we engineer therapeutic bacteria controlled by a temperature-actuated genetic switch. Brief exposure to focused ultrasound (US) hyperthermia activates this switch, driving sustained CCL21 release to recruit immune cells. These bacteria are surface-modified for bromelain conjugation and bacterial "backpack" formation on macrophages. Following in vitro co-incubation, bacteria-loaded macrophages are intravenously administered for tumor-targeted delivery. In vivo experiments confirm that system activation promotes macrophage repolarization toward a CD86-expressing phenotype within the TME and enhances immune cell infiltration. Moreover, treatment reduces collagen I deposition, weakens the mechanobiological properties of tumor cells, and mitigates tumor-mediated immune evasion. Collectively, this system remodels the immunosuppressive TME through macrophage-mediated bacterial delivery and US-triggered CCL21 release, facilitating dendritic cell and CD4+/CD8+ T cell infiltration and improving antitumor immunotherapy.